http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2512476-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_44c713790ce00813da2e6c6d57a29456 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-401 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-16 |
filingDate | 2001-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f5b5e43e70b3e02959291d02929a06a2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09d411ceee278221de02913dae10f912 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0458971ce127e06e9c1b52d9cb6bab3d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_909420b85823075bb65a7b8289ab9712 |
publicationDate | 2002-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CA-2512476-A1 |
titleOfInvention | Cyanopyrrolidine derivatives |
abstract | A cynaopyrrolidine derivative and pharmaceutical compositions containing same for inhibiting dipeptidyl peptidase IV to treat conditions such as diabetes mellitus and immune diseases. The derivative is represented by Formula (1): (see formula 1) wherein R1 is a halogen atom, a hydroxyl group, an alkoxy group having 1 to 5 carbon atoms or an alkyl group having 1 to 5 carbon atoms; R2 is a hydrogen atom, a halogen atom, a hydroxyl group, an alkoxy group having 1 to 5 carbon atoms or an alkyl group having 1 to 5 carbon atoms; or R1 and R2 together form an oxo, a hydroxyimino group, an alkoxyimino group having 1 to 5 carbon atoms or an alkylidene group having 1 to 5 carbon atoms; R3 and R4 are each a hydrogen atom, a halogen atom, a hydroxyl group, an alkoxy group having 1 to 5 carbon atoms or an alkyl group having 1 to 5 carbon atoms; or R3 and R4 together form an oxo, a hydroxyimino group, an alkoxyimino group having 1 to 5 carbon atoms or an alkylidene group having 1 to 5 carbon atoms; X is an oxygen atom or a sulfur atom; Y is -CR5R6- wherein R5 and R6 are the same or different, and are each a hydrogen atom, a halogen atom, an optionally substituted alkyl group having 1 to 10 carbon atoms or an optionally substituted alkenyl group having 2 to 10 carbon atoms; or -CR7R8-wherein R7, R8, R9 and R10 are the same or different, and each a hydrogen atom, a halogen atom or an optionally substituted alkyl group having 1 to 10 carbon atoms; or R7 and R9 together with the carbon atom to which they are attached form an optionally substituted cycloalkyl group having 3 to 8 carbon atoms, an optionally substituted cycloalkenyl group having 4 to 8 carbon atoms; an optionally substituted bicycloalkyl group having 5 to 10 carbon atoms, or an optionally substituted bicycloalkenyl group having 5 to 10 carbon atoms; and Z is a hydrogen atom or an optionally substituted alkyl group having 1 to 10 carbon atoms, or Y and Z together with the nitrogen atom to which they are attached form an optionally substituted cyclic amino group having 2 to 10 carbon atoms; or a pharmaceutically acceptable salt thereof. |
priorityDate | 2000-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 506.